Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) – Equities research analysts at Leerink Swann issued their Q1 2018 earnings estimates for shares of Alder BioPharmaceuticals in a note issued to investors on Tuesday. Leerink Swann analyst P. Matteis expects that the biopharmaceutical company will earn ($1.00) per share for the quarter. Leerink Swann also issued estimates for Alder BioPharmaceuticals’ Q2 2018 earnings at ($1.03) EPS, Q3 2018 earnings at ($0.84) EPS, Q4 2018 earnings at ($0.77) EPS and FY2019 earnings at ($3.34) EPS.
Several other research analysts also recently commented on ALDR. Needham & Company LLC set a $36.00 price target on shares of Alder BioPharmaceuticals and gave the stock a “buy” rating in a research note on Monday, July 17th. Zacks Investment Research downgraded shares of Alder BioPharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, August 8th. BMO Capital Markets reissued an “outperform” rating and set a $27.00 price target (down from $39.00) on shares of Alder BioPharmaceuticals in a research note on Wednesday, August 9th. Credit Suisse Group set a $11.00 price target on shares of Alder BioPharmaceuticals and gave the stock a “hold” rating in a research note on Thursday, August 24th. Finally, BidaskClub raised shares of Alder BioPharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, August 25th. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and eleven have given a buy rating to the company. Alder BioPharmaceuticals currently has an average rating of “Buy” and an average target price of $28.07.
TRADEMARK VIOLATION WARNING: “Alder BioPharmaceuticals, Inc. to Post Q1 2018 Earnings of ($1.00) Per Share, Leerink Swann Forecasts (ALDR)” was first published by Transcript Daily and is owned by of Transcript Daily. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://transcriptdaily.com/2017/11/10/alder-biopharmaceuticals-inc-to-post-q1-2018-earnings-of-1-00-per-share-leerink-swann-forecasts-aldr.html.
Alder BioPharmaceuticals (ALDR) traded down $0.07 during mid-day trading on Thursday, hitting $11.13. 159,929 shares of the company’s stock traded hands, compared to its average volume of 1,137,633. Alder BioPharmaceuticals has a 52-week low of $8.60 and a 52-week high of $34.30.
Alder BioPharmaceuticals (NASDAQ:ALDR) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.92) EPS for the quarter, topping the consensus estimate of ($1.21) by $0.29. During the same quarter in the previous year, the company earned ($0.70) EPS.
Several institutional investors have recently modified their holdings of ALDR. Quantitative Systematic Strategies LLC bought a new position in shares of Alder BioPharmaceuticals in the third quarter worth approximately $132,000. Legal & General Group Plc boosted its holdings in Alder BioPharmaceuticals by 2.6% in the second quarter. Legal & General Group Plc now owns 15,496 shares of the biopharmaceutical company’s stock valued at $177,000 after acquiring an additional 400 shares in the last quarter. SG Americas Securities LLC boosted its holdings in Alder BioPharmaceuticals by 109.4% in the second quarter. SG Americas Securities LLC now owns 15,580 shares of the biopharmaceutical company’s stock valued at $178,000 after acquiring an additional 8,140 shares in the last quarter. Voya Investment Management LLC boosted its holdings in Alder BioPharmaceuticals by 8.4% in the second quarter. Voya Investment Management LLC now owns 22,304 shares of the biopharmaceutical company’s stock valued at $255,000 after acquiring an additional 1,734 shares in the last quarter. Finally, Cornerstone Capital Management Holdings LLC. boosted its holdings in Alder BioPharmaceuticals by 13.4% in the second quarter. Cornerstone Capital Management Holdings LLC. now owns 30,520 shares of the biopharmaceutical company’s stock valued at $349,000 after acquiring an additional 3,616 shares in the last quarter. Hedge funds and other institutional investors own 78.57% of the company’s stock.
In other news, insider Mark James Litton sold 16,520 shares of the firm’s stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $12.33, for a total value of $203,691.60. Following the transaction, the insider now owns 116,452 shares in the company, valued at $1,435,853.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.60% of the stock is currently owned by company insiders.
About Alder BioPharmaceuticals
Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.
Receive News & Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.